# Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

> **NCT05657860** · PHASE4 · COMPLETED · sponsor: **Maimonides Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Prader-Willi Syndrome
- Aggression
- Self-Injurious Behavior
- Pathologic Processes
- Behavioral Symptoms
- Intellectual Disability
- Neurobehavioral Manifestations
- Neurologic Manifestations
- Nervous System Diseases
- Abnormalities, Multiple
- Congenital Abnormalities
- Chromosome Disorders
- Genetic Diseases, Inborn
- Obesity
- Overnutrition
- Nutrition Disorders
- Antihypertensive Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Physiological Effects of Drugs
- Skin-Picking

## Interventions

- **DRUG:** Guanfacine Extended Release
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05657860
- **Lead sponsor:** Maimonides Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2023-12-16
- **Final completion:** 2023-12-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05657860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05657860, "Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05657860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*